IMPower010

Home Tag

WCLC2022

IMpower010: pre-specified interim analysis of overall survival further support adjuvant atezolizumab in early-stage resected NSCLC

The first pre-specified interim analysis of overall survival data from the phase III IMpower010 trial shows a trend in favor…

Enriqueta

ecancer catches up with VHIO’s Enriqueta Felip & Cristina Saura on new therapeutic avenues against NSCLC and breast cancer, respectively

Reflective of the relevance of just some of the many VHIO-led studies presented during last week’s virtual 2021 Annual Congress…